Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Fig. 4

sBCMA plasma levels dynamics following ide-cel infusion. Longitudinal monitoring of sBCMA plasma levels using the human BCMA/TNFRSF17 ELISA assay and correlation with tumor responses A in patients reaching an objective response and B in non-responders. Green: patients with sCR; Blue: patients with CR; Magenta: patients with VGPR; red: patients with PD. Abbreviations: CR: complete response; PD: progressive disease; sCR: stringent complete response; VGPR: very good partial response

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us